Foghorn Therapeutics Raises $50M in Direct Offering Priced at Premium to Market
FHTX has more than doubled off its 52-week low of $2.945.
Summary
Foghorn Therapeutics Inc. announced a direct offering of common stock and warrants, raising approximately $50 million in gross proceeds at an offering price of $6.71 per share, which is a premium to the current market price.
Key Events · Financing and Capital Events · FHTX
-
Significant Capital Raise
Foghorn Therapeutics is raising approximately $50.0 million in gross proceeds through a direct offering of common stock and warrants.
-
Premium Offering Price
The common stock and pre-funded warrants are being sold at an offering price of $6.71 per share, which is a premium to the current market price of $6.27.
-
Substantial Dilution
The offering includes 2,030,314 shares of common stock and warrants to purchase an additional 12,872,814 shares, leading to significant potential dilution for existing shareholders.
-
Funding for Programs
Net proceeds of approximately $49.6 million will be used to advance the company's preclinical and clinical programs and for general corporate purposes.
Analysis · FHTX · Life Sciences
This significant capital raise provides Foghorn Therapeutics with approximately $49.6 million in net proceeds to fund its preclinical and clinical programs and for general corporate purposes. The offering price of $6.71 per share, which is above the current trading price of $6.27, indicates strong investor confidence in the company's valuation and future prospects. While the offering is highly dilutive, the successful securing of substantial capital at a premium is a positive development for a clinical-stage biotechnology company, extending its operational runway and supporting its pipeline development without incurring underwriting fees.
How filings like this one have moved
In the 30 days to Sep 25, 2026, 35.1% of the 1036 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FHTX was trading at $6.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $360.8M. The 52-week trading range was $2.94 to $6.79. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.